NCT01286909

Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Omicron Pharmaceuticals · Industry
• Sex: All
• Age: 45 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).

Conditions

• Metabolic Disease

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	LaFlavon	two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months

Timeline

• Start date: 2011-01-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2011-01-31
• Last updated: 2011-02-10

Locations

1 site across 1 country: Lebanon